Stem definition | Drug id | CAS RN |
---|---|---|
719 | 23593-75-1 |
Dose | Unit | Route |
---|---|---|
0.10 | g | V |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 5 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.07 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 3, 1975 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Macular degeneration | 452.65 | 13.31 | 157 | 11529 | 14231 | 50579207 |
Schizoaffective disorder | 236.37 | 13.31 | 62 | 11624 | 2144 | 50591294 |
Drug level increased | 124.78 | 13.31 | 69 | 11617 | 19199 | 50574239 |
Electrocardiogram QT prolonged | 67.46 | 13.31 | 71 | 11615 | 51815 | 50541623 |
Sinus rhythm | 45.36 | 13.31 | 13 | 11673 | 627 | 50592811 |
Vanishing bile duct syndrome | 40.97 | 13.31 | 12 | 11674 | 625 | 50592813 |
Eye infection toxoplasmal | 40.48 | 13.31 | 10 | 11676 | 270 | 50593168 |
Vulvovaginal candidiasis | 39.88 | 13.31 | 17 | 11669 | 2675 | 50590763 |
Oral candidiasis | 33.07 | 13.31 | 29 | 11657 | 16886 | 50576552 |
Purpura senile | 29.82 | 13.31 | 9 | 11677 | 520 | 50592918 |
Vulvovaginal inflammation | 28.68 | 13.31 | 9 | 11677 | 593 | 50592845 |
Tongue blistering | 28.45 | 13.31 | 11 | 11675 | 1347 | 50592091 |
Febrile neutropenia | 27.50 | 13.31 | 66 | 11620 | 97601 | 50495837 |
Tarsal tunnel syndrome | 25.43 | 13.31 | 8 | 11678 | 531 | 50592907 |
Swollen tongue | 23.54 | 13.31 | 31 | 11655 | 28599 | 50564839 |
Candida infection | 23.37 | 13.31 | 28 | 11658 | 23495 | 50569943 |
Angiodermatitis | 22.96 | 13.31 | 5 | 11681 | 76 | 50593362 |
Drug interaction | 21.37 | 13.31 | 97 | 11589 | 199524 | 50393914 |
Post viral fatigue syndrome | 20.80 | 13.31 | 6 | 11680 | 296 | 50593142 |
Resorption bone increased | 20.51 | 13.31 | 8 | 11678 | 1003 | 50592435 |
Swelling of eyelid | 18.81 | 13.31 | 9 | 11677 | 1851 | 50591587 |
Aplastic anaemia | 18.77 | 13.31 | 15 | 11671 | 7688 | 50585750 |
Vestibular disorder | 18.75 | 13.31 | 8 | 11678 | 1261 | 50592177 |
Reperfusion arrhythmia | 17.59 | 13.31 | 5 | 11681 | 234 | 50593204 |
Therapeutic product effect decreased | 17.26 | 13.31 | 5 | 11681 | 136045 | 50457393 |
Chronic sinusitis | 17.22 | 13.31 | 13 | 11673 | 6132 | 50587306 |
Rheumatoid arthritis | 17.18 | 13.31 | 13 | 11673 | 202537 | 50390901 |
Glossodynia | 17.16 | 13.31 | 3 | 11683 | 115566 | 50477872 |
Stevens-Johnson syndrome | 17.03 | 13.31 | 23 | 11663 | 21729 | 50571709 |
Conjunctivitis | 15.68 | 13.31 | 19 | 11667 | 16126 | 50577312 |
Toxicity to various agents | 15.19 | 13.31 | 16 | 11670 | 212483 | 50380955 |
Vulvovaginal discomfort | 15.13 | 13.31 | 8 | 11678 | 2033 | 50591405 |
Congenital absence of bile ducts | 15.12 | 13.31 | 3 | 11683 | 28 | 50593410 |
Dysuria | 14.96 | 13.31 | 25 | 11661 | 28479 | 50564959 |
Neuropathy peripheral | 14.31 | 13.31 | 52 | 11634 | 96705 | 50496733 |
Oedema mouth | 14.26 | 13.31 | 8 | 11678 | 2282 | 50591156 |
Treatment failure | 14.22 | 13.31 | 7 | 11679 | 137630 | 50455808 |
Swelling face | 14.21 | 13.31 | 35 | 11651 | 52560 | 50540878 |
Stoma site haemorrhage | 14.13 | 13.31 | 6 | 11680 | 935 | 50592503 |
Post transplant distal limb syndrome | 14.05 | 13.31 | 4 | 11682 | 188 | 50593250 |
Foetal death | 13.97 | 13.31 | 13 | 11673 | 8167 | 50585271 |
Urinary tract infection | 13.95 | 13.31 | 94 | 11592 | 223926 | 50369512 |
Mouth ulceration | 13.94 | 13.31 | 24 | 11662 | 28000 | 50565438 |
Vertigo positional | 13.58 | 13.31 | 8 | 11678 | 2503 | 50590935 |
Exfoliative rash | 13.52 | 13.31 | 8 | 11678 | 2522 | 50590916 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cellulitis | 22.87 | 15.93 | 36 | 5792 | 45804 | 29522895 |
Skin infection | 20.72 | 15.93 | 14 | 5814 | 6513 | 29562186 |
Lip haemorrhage | 20.20 | 15.93 | 7 | 5821 | 738 | 29567961 |
Accident | 19.62 | 15.93 | 11 | 5817 | 3677 | 29565022 |
Rash pruritic | 19.44 | 15.93 | 23 | 5805 | 22340 | 29546359 |
Aplastic anaemia | 18.95 | 15.93 | 14 | 5814 | 7496 | 29561203 |
Temperature regulation disorder | 17.82 | 15.93 | 6 | 5822 | 580 | 29568119 |
Microtia | 17.56 | 15.93 | 5 | 5823 | 277 | 29568422 |
Congenital umbilical hernia | 17.37 | 15.93 | 5 | 5823 | 288 | 29568411 |
Lymphopenia | 17.17 | 15.93 | 17 | 5811 | 13516 | 29555183 |
Leukopenia | 16.83 | 15.93 | 35 | 5793 | 55168 | 29513531 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Vulvovaginal candidiasis | 44.62 | 13.53 | 17 | 14096 | 2113 | 64482506 |
Aplastic anaemia | 39.42 | 13.53 | 29 | 14084 | 13891 | 64470728 |
Eye infection toxoplasmal | 35.53 | 13.53 | 10 | 14103 | 477 | 64484142 |
Vanishing bile duct syndrome | 33.40 | 13.53 | 12 | 14101 | 1265 | 64483354 |
Oral candidiasis | 32.00 | 13.53 | 32 | 14081 | 23180 | 64461439 |
Rash pruritic | 31.68 | 13.53 | 50 | 14063 | 57354 | 64427265 |
Tongue blistering | 29.55 | 13.53 | 11 | 14102 | 1282 | 64483337 |
Febrile neutropenia | 26.70 | 13.53 | 96 | 14017 | 187561 | 64297058 |
Drug ineffective | 26.41 | 13.53 | 95 | 14018 | 840152 | 63644467 |
Tarsal tunnel syndrome | 26.37 | 13.53 | 8 | 14105 | 497 | 64484122 |
Purpura senile | 26.28 | 13.53 | 8 | 14105 | 503 | 64484116 |
Toxicity to various agents | 25.71 | 13.53 | 25 | 14088 | 363488 | 64121131 |
Swollen tongue | 24.40 | 13.53 | 34 | 14079 | 34920 | 64449699 |
Angiodermatitis | 23.36 | 13.53 | 5 | 14108 | 74 | 64484545 |
Candida infection | 22.59 | 13.53 | 31 | 14082 | 31388 | 64453231 |
Stevens-Johnson syndrome | 21.97 | 13.53 | 32 | 14081 | 34217 | 64450402 |
Post viral fatigue syndrome | 21.08 | 13.53 | 6 | 14107 | 298 | 64484321 |
Swelling of eyelid | 20.86 | 13.53 | 10 | 14103 | 2182 | 64482437 |
Gingival swelling | 20.52 | 13.53 | 12 | 14101 | 3908 | 64480711 |
Overdose | 20.23 | 13.53 | 5 | 14108 | 159561 | 64325058 |
Resorption bone increased | 19.81 | 13.53 | 8 | 14105 | 1160 | 64483459 |
Vulvovaginal inflammation | 18.38 | 13.53 | 6 | 14107 | 474 | 64484145 |
Urinary tract infection | 18.06 | 13.53 | 99 | 14014 | 231497 | 64253122 |
Wound complication | 17.85 | 13.53 | 11 | 14102 | 3937 | 64480682 |
Oral mucosal blistering | 17.34 | 13.53 | 12 | 14101 | 5225 | 64479394 |
Reperfusion arrhythmia | 16.87 | 13.53 | 5 | 14108 | 287 | 64484332 |
Lip haemorrhage | 16.60 | 13.53 | 7 | 14106 | 1132 | 64483487 |
Plicated tongue | 16.59 | 13.53 | 4 | 14109 | 103 | 64484516 |
Pruritus | 15.98 | 13.53 | 120 | 13993 | 312280 | 64172339 |
Therapeutic product effect decreased | 15.87 | 13.53 | 3 | 14110 | 115348 | 64369271 |
Cellulitis | 15.12 | 13.53 | 50 | 14063 | 93607 | 64391012 |
Genital rash | 14.90 | 13.53 | 6 | 14107 | 863 | 64483756 |
Swelling face | 14.82 | 13.53 | 37 | 14076 | 59129 | 64425490 |
Kidney transplant rejection | 14.77 | 13.53 | 14 | 14099 | 9497 | 64475122 |
Vestibular disorder | 14.66 | 13.53 | 8 | 14105 | 2285 | 64482334 |
Vulvovaginal discomfort | 14.51 | 13.53 | 7 | 14106 | 1548 | 64483071 |
Accident | 14.47 | 13.53 | 12 | 14101 | 6834 | 64477785 |
Rash | 14.20 | 13.53 | 158 | 13955 | 458391 | 64026228 |
Post transplant distal limb syndrome | 13.94 | 13.53 | 5 | 14108 | 525 | 64484094 |
Nephrogenic systemic fibrosis | 13.88 | 13.53 | 11 | 14102 | 5881 | 64478738 |
Vulvovaginal pain | 13.83 | 13.53 | 7 | 14106 | 1715 | 64482904 |
Foetal death | 13.81 | 13.53 | 11 | 14102 | 5919 | 64478700 |
Blister | 13.77 | 13.53 | 44 | 14069 | 80923 | 64403696 |
Faeces discoloured | 13.63 | 13.53 | 22 | 14091 | 25707 | 64458912 |
Mouth ulceration | 13.58 | 13.53 | 25 | 14088 | 32419 | 64452200 |
None
Source | Code | Description |
---|---|---|
ATC | A01AB18 | ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS Antiinfectives and antiseptics for local oral treatment |
ATC | D01AC01 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
ATC | G01AF02 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
FDA CS | M0002083 | Azoles |
FDA EPC | N0000175487 | Azole Antifungal |
CHEBI has role | CHEBI:35441 | antiinfective agents |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:78298 | environmental contaminants |
MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000891 | Anti-Infective Agents, Local |
MeSH PA | D000935 | Antifungal Agents |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D065088 | Steroid Synthesis Inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tinea pedis | indication | 6020002 | DOID:12403 |
Candidiasis of skin | indication | 49883006 | |
Pityriasis versicolor | indication | 56454009 | DOID:9060 |
Candidal vulvovaginitis | indication | 72605008 | DOID:2272 |
Candidiasis of mouth | indication | 79740000 | DOID:14262 |
Tinea corporis | indication | 84849002 | |
Diaper rash | indication | 91487003 | |
Tinea cruris | indication | 399029005 | |
Prevention of Oropharyngeal Candidiasis | indication | ||
Oropharyngeal Candidiasis | indication | ||
Paronychia | off-label use | 71906005 | DOID:13117 |
Telangiectasia disorder | contraindication | 247479008 | |
Abdominal pain - cause unknown | contraindication | 314212008 | |
Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
Atrophoderma | contraindication | 399979006 | |
Peripheral vascular disease | contraindication | 400047006 |
Species | Use | Relation |
---|---|---|
Cats | Fungal infections caused by Microsporum canis | Indication |
Cats | Fungal infections caused by Trichophyton mentagrophytes | Indication |
Cats | Otitis externa caused by yeast, Malassezia pachydermatis | Indication |
Dogs | Fungal infections caused by Microsporum canis | Indication |
Dogs | Fungal infections caused by Trichophyton mentagrophytes | Indication |
Product | Applicant | Ingredients |
---|---|---|
Veltrim 1% Dermatologic Cream | Elanco US Inc. | 1 |
Otomax | Intervet Inc. | 3 |
Mometamax Otic Suspension | Intervet Inc. | 3 |
Tri-Otic Ointment | Med-Pharmex Inc. | 3 |
Vetro-Max | Fougera Pharmaceuticals Inc. | 3 |
GBC Ointment | Cronus Pharma Specialities India Private Limited | 3 |
Mometavet | Med-Pharmex Inc. | 3 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.4 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Beta-1 adrenergic receptor | GPCR | Ki | 5.19 | DRUG MATRIX | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.38 | DRUG MATRIX | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | ANTAGONIST | IC50 | 6.16 | IUPHAR | ||||
Mu-type opioid receptor | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.39 | DRUG MATRIX | |||||
Adenosine receptor A2a | GPCR | Ki | 5.15 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 5.35 | DRUG MATRIX | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.52 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 7.70 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | IC50 | 5.17 | WOMBAT-PK | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.51 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.10 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.00 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.50 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 5.12 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.43 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.05 | DRUG MATRIX | |||||
Histamine H1 receptor | GPCR | Ki | 5.47 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.29 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 5.78 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.29 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
Glucocorticoid receptor | Nuclear hormone receptor | Ki | 5.83 | DRUG MATRIX | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.27 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.35 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 5.11 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.57 | DRUG MATRIX | |||||
Intermediate conductance calcium-activated potassium channel protein 4 | Ion channel | IC50 | 7.15 | CHEMBL | |||||
Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | WOMBAT-PK | |||||||
D(4) dopamine receptor | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
Carbonic anhydrase 2 | Enzyme | IC50 | 4.52 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.13 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.60 | DRUG MATRIX | |||||
Delta-type opioid receptor | GPCR | Ki | 5.76 | DRUG MATRIX | |||||
Acetylcholinesterase | Enzyme | IC50 | 4.71 | DRUG MATRIX | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Platelet-activating factor receptor | GPCR | Ki | 4.65 | DRUG MATRIX | |||||
Aromatase | Enzyme | IC50 | 8.74 | CHEMBL | |||||
Cysteinyl leukotriene receptor 1 | GPCR | Ki | 4.78 | CHEMBL | |||||
Epidermal growth factor receptor | Kinase | IC50 | 4.16 | DRUG MATRIX | |||||
Vasopressin V2 receptor | GPCR | IC50 | 5.60 | CHEMBL | |||||
Substance-P receptor | GPCR | Ki | 5.06 | DRUG MATRIX | |||||
Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | IC50 | 7.09 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily A member 3 | Ion channel | IC50 | 5.22 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 7.80 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 4.50 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 4.18 | DRUG MATRIX | |||||
Thromboxane-A synthase | Enzyme | IC50 | 7.85 | DRUG MATRIX | |||||
Bile acid receptor | Nuclear hormone receptor | IC50 | 5.49 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | IC50 | 6.89 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.92 | CHEMBL | |||||
Substance-K receptor | GPCR | Ki | 5.47 | DRUG MATRIX | |||||
C-C chemokine receptor type 4 | GPCR | IC50 | 5.80 | CHEMBL | |||||
C-X-C chemokine receptor type 1 | GPCR | IC50 | 5.70 | CHEMBL | |||||
Transitional endoplasmic reticulum ATPase | Enzyme | IC50 | 5.85 | CHEMBL | |||||
Malate dehydrogenase cytoplasmic | Enzyme | IC50 | 4.46 | CHEMBL | |||||
7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | IC50 | 6.10 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Beta-lactamase | Enzyme | IC50 | 4.70 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 5.11 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1B | GPCR | Ki | 4.91 | DRUG MATRIX | |||||
Cysteinyl leukotriene receptor 1 | GPCR | Ki | 4.78 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.94 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 4.58 | CHEMBL | |||||
Lanosterol 14-alpha demethylase | Enzyme | Kd | 6.70 | CHEMBL | |||||
14-alpha sterol demethylase Cyp51A | Enzyme | Kd | 5.32 | CHEMBL | |||||
14-alpha sterol demethylase | Enzyme | Kd | 6.99 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 2 | Enzyme | IC50 | 5.23 | CHEMBL | |||||
Mycocyclosin synthase | Enzyme | Kd | 7.14 | CHEMBL | |||||
Putative cytochrome P450 130 | Enzyme | Kd | 4.88 | CHEMBL | |||||
Alpha-chymotrypsin | Enzyme | IC50 | 4.07 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.29 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.75 | CHEMBL | |||||
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | Enzyme | Ki | 4.46 | CHEMBL |
ID | Source |
---|---|
4018265 | VUID |
N0000146595 | NUI |
D00282 | KEGG_DRUG |
202859 | RXNORM |
4018265 | VANDF |
C0009074 | UMLSCUI |
CHEBI:3764 | CHEBI |
CL6 | PDB_CHEM_ID |
CHEMBL104 | ChEMBL_ID |
DB00257 | DRUGBANK_ID |
D003022 | MESH_DESCRIPTOR_UI |
2812 | PUBCHEM_CID |
2330 | IUPHAR_LIGAND_ID |
2912 | INN_ID |
G07GZ97H65 | UNII |
1284 | MMSL |
4482 | MMSL |
d01236 | MMSL |
002916 | NDDF |
387325003 | SNOMEDCT_US |
5797005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-4146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0054-8146 | LOZENGE | 10 mg | ORAL | ANDA | 14 sections |
Lotrisone | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0085-0924 | CREAM | 10 mg | TOPICAL | NDA | 26 sections |
Good Sense Athletes Footantifungal | HUMAN OTC DRUG LABEL | 1 | 0113-0857 | CREAM | 1 g | TOPICAL | OTC monograph final | 13 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0133 | CREAM | 10 mg | TOPICAL | ANDA | 20 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0168-0258 | CREAM | 10 mg | TOPICAL | ANDA | 27 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0168-0370 | LOTION | 10 mg | TOPICAL | ANDA | 20 sections |
Fungicure Liquid Gel | HUMAN OTC DRUG LABEL | 1 | 0295-1363 | LIQUID | 10 mg | TOPICAL | OTC monograph final | 9 sections |
Fungicure Manicure Pedicure Anti Fungal | HUMAN OTC DRUG LABEL | 1 | 0295-6307 | LIQUID | 1 mg | TOPICAL | OTC monograph final | 10 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
WALGREENS CLOTRIMAZOLE | HUMAN OTC DRUG LABEL | 1 | 0363-1299 | CREAM | 1 g | TOPICAL | OTC monograph final | 11 sections |
athletes foot | HUMAN OTC DRUG LABEL | 1 | 0363-1857 | CREAM | 1 g | TOPICAL | OTC monograph final | 13 sections |
Walgreens Clotrimazole 3 | HUMAN OTC DRUG LABEL | 1 | 0363-2062 | CREAM | 2 g | VAGINAL | NDA | 16 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-2105 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Ringworm | HUMAN OTC DRUG LABEL | 1 | 0363-2107 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Walgreens Jock Itch | HUMAN OTC DRUG LABEL | 1 | 0363-2109 | CREAM | 10 mg | TOPICAL | OTC MONOGRAPH FINAL | 14 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0363-3492 | LIQUID | 1 mg | TOPICAL | OTC monograph final | 8 sections |
Walgreens Clotrimazole Antifungal | HUMAN OTC DRUG LABEL | 1 | 0363-7412 | CREAM | 1 g | TOPICAL | OTC monograph final | 11 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0472-0220 | CREAM | 10 mg | VAGINAL | ANDA | 16 sections |
ClotrimazoleAntifungal | HUMAN OTC DRUG LABEL | 1 | 0472-0350 | CREAM | 10 mg | TOPICAL | OTC monograph final | 13 sections |
Clotrimazole and Betamethasone Dipropionate | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0472-0379 | CREAM | 10 mg | TOPICAL | ANDA | 24 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0536-1181 | SOLUTION | 1 g | TOPICAL | OTC monograph final | 13 sections |
Rugby Clotrimazole Antifungal Cream | HUMAN OTC DRUG LABEL | 1 | 0536-1265 | CREAM | 1 g | TOPICAL | OTC monograph final | 12 sections |
RUGBY ANTIFUNGAL CLOTRIMAZOLE | HUMAN OTC DRUG LABEL | 1 | 0536-1272 | CREAM | 0.01 g | TOPICAL | OTC monograph final | 14 sections |
Clotrimazole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-0107 | LOZENGE | 10 mg | ORAL | ANDA | 18 sections |
Major Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 0904-7822 | CREAM | 10 mg | TOPICAL | OTC monograph final | 11 sections |
Clotrimazole | HUMAN OTC DRUG LABEL | 1 | 10135-671 | SOLUTION | 1 g | TOPICAL | OTC monograph final | 13 sections |
Lotrimin | HUMAN OTC DRUG LABEL | 1 | 11523-0963 | CREAM | 10 mg | TOPICAL | OTC monograph final | 14 sections |
LotriminAntifungal | HUMAN OTC DRUG LABEL | 1 | 11523-1125 | CREAM | 10 mg | TOPICAL | OTC monograph final | 14 sections |
Lotrimin | HUMAN OTC DRUG LABEL | 1 | 11523-6549 | CREAM | 10 mg | TOPICAL | OTC monograph final | 14 sections |